Valeant Pharmaceuticals Announces Management Change

Mar 02, 2016, 19:01 ET from Valeant Pharmaceuticals International, Inc.

LAVAL, Quebec, March 2, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today confirmed that Deb Jorn has resigned as Executive Vice President, Company Group Chairman, effective immediately. In this role, she was responsible for running the company's U.S. Dermatology and Gastrointestinal businesses. Eric Abramson, Vice President Dermatology & Immunology Marketing, has been appointed General Manager of the U.S. Dermatology business and Dr. Ari Kellen, Executive Vice President and Company Group Chairman will oversee Valeant's gastrointestinal business.

About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be at

Contact Information:

Laurie W. Little                                              949-461-6002     

Elif McDonald 905-695-7607

Media: Renée E. Soto/Meghan Gavigan Sard Verbinnen & Co. 212-687-8080 /

Logo -


SOURCE Valeant Pharmaceuticals International, Inc.